CLINICAL TRIALS PROFILE FOR INDIGOTINDISULFONATE SODIUM
✉ Email this page to a colleague
All Clinical Trials for indigotindisulfonate sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01767415 ↗ | Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection | Completed | Weill Medical College of Cornell University | Phase 1/Phase 2 | 2012-04-01 | The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection. |
| NCT02677623 ↗ | Evaluation of Ureteral Patency in the Post-indigo Carmine Era | Completed | Columbia University | Phase 4 | 2015-03-01 | Many gynecologic, urologic and pelvic reconstructive surgeries require accurate ways to identify the opening of the ureters to ensure that they are working correctly. Historically, indigo carmine, an intravenous medication that dyes the urine blue, has been used to help visualize the opening of the ureters with cystoscopy which is a camera placed inside the bladder. In June 2014, the FDA announced there was current shortage of indigo carmine. Thus, investigators need to evaluate other methods for assessing ureteral patency. Ideal alternatives are agents that are low-risk, inexpensive, provide comparable visualization, are readily available and are easy to use. Examples of such agents currently being used to evaluate the ureters, include oral pyridium, IV sodium fluorescein, and mannitol. These agents help identify the opening of the ureters by either dyeing the urine a different color such as pyridium and sodium fluorescein, or by having a different viscosity to urine such as mannitol. This study will compare three methods of evaluating ureteral patency at time of cystoscopy compared to no method: mannitol, sodium fluorescein, and pyridium. |
| NCT03065075 ↗ | Effect of Phenazopyridine on Prolapse Surgery Voiding Trials | Completed | University of Massachusetts, Worcester | Phase 3 | 2017-02-01 | To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for indigotindisulfonate sodium
Condition Name
Clinical Trial Locations for indigotindisulfonate sodium
Trials by Country
Clinical Trial Progress for indigotindisulfonate sodium
Clinical Trial Phase
Clinical Trial Sponsors for indigotindisulfonate sodium
Sponsor Name
